BioPlus Acquisition Corporation (BIOSU) News

Form 15-12G - Securities registration termination [Section 12(g)]

Form RW - Registration Withdrawal Request

Form 8-K - Current report

BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate

New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (“BIOS” or the “Company”) (Nasdaq: BIOS) announced today that (i...

Form 425 - Prospectuses and communications, business combinations

Form 425 - Prospectuses and communications, business combinations

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 425 - Prospectuses and communications, business combinations

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K    ...

Current Report Filing (8-k)

false 0001856653 0001856653 2023-06-14 2023-06-14 0001856653 us-gaap:CapitalUnitsMember 2023-06-14 2023-06-14 0001856653...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K  ...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filed by BioPlus Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filed by BioPlus Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to...

Quarterly Report (10-q)

falseQ10001856653--12-31NY 0001856653 2023-01-01 2023-03-31 0001856653 2022-01-01 2022-03-31 0001856653 2023-03-31 0001856653 2022-12-31...

Securities Registration: Business Combination (s-4)

Table of Contents false0001856653 0001856653 2022-01-01 2022-12-31 0001856653 2021-02-11 2021-12-31...